(All fields required)
Please enter a valid email.
Please enter your name.
What is : (So we know you are human.)
Please supply the correct answer.
The Division of Nephrology and Hypertension at Cincinnati Children's has had a long-standing interest in the relationship between the human complement system and immune-mediated renal disease. Founded by complement biology pioneer Dr. Clark West, our Clinical Laboratory provides a number of measurements helpful in the diagnosis and management of the glomerulonephritides, complement deficiencies, iron deficiency, the dysgammaglobulinemias, immunoglobulin subclass deficiencies, systemic lupus erythematosus, therapy-induced immune deficiencies, and hereditary angioedema.
One focus of the Clinical Laboratory born out of the expertise in complement-mediated renal diseases is clinical testing for the thrombotic microangiopathies (TMA), specifically atypical hemolytic uremic syndrome (aHUS) and thrombotic thrombocytopenic purpura (TTP). This, guided by the clinical expertise in diagnostic testing of aHUS and TTP offered by Bradley Dixon, MD, has led to partnerships with the Cancer and Blood Diseases Institute and Molecular Genetics Laboratory at Cincinnati Children's to provide a comprehensive laboratory testing platform for these diseases.
Our clinical lab technicians are certified by the American Society for Clinical Pathology (ASCP) and have a combined 35 years of experience in clinical testing.
The Nephrology Clinical Lab also partners with the Biomarker Laboratory to conduct front-line research into discovering diagnostic markers of disease that will lead to earlier and more accurate diagnoses, allowing physicians to better treat patients.
The Biomarker Laboratory is housed in the Division of Nephrology and Hypertension and was born out of the shared discovery of neutrophil gelatinase-associated lipocalin (NGAL) as a promising new early diagnostic marker of kidney injury. Our goals are to usher pediatrics into the era of individualized medicine. In addition to original research into the discovery and validation of biomarkers of acute kidney injury and chronic kidney disease, the biomarker research laboratory assists investigators across Cincinnati Children's and around the globe in all stages of biomarker research as collaborations or fee for service, from pre-clinical discovery and assay development to validation in clinical trials.
Cincinnati Children's Hospital Medical Center Division of Nephrology and Hypertension MLC 7022 3333 Burnet Ave. Cincinnati, OH 45229-3039
Access our Clinical Laboratory Test Index.
Our clinical laboratory offers several options for the testing of samples that we receive from patients. Each test is specific, and some require different sample types.
The Nephrology Clinical Laboratory is pleased to announce the availability of quantitative testing of eculizumab in serum. This ELISA-based testing methodology measures the free level of eculizumab (Soliris®, Alexion Pharmaceuticals), a humanized monoclonal antibody directed against the complement protein C5 which is FDA approved for the treatment of paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS). Learn more under "Eculizumab."
Download the Nephrology Laboratory Requisition Form
Download the TMA Requisition Form
Download the Eculizumab Testing Fact Sheet
The Nephrology Clinical Laboratory now offers testing for PLA2R autoantibodies. Learn more under "PLA2R Autoanitbody."
Download the Nephrology Laboratory Requisition Form.
Learn more about the PLA2R Autoantibodies Diagnostic Marker for Membranous Nephropathy.
3333 Burnet Avenue, Cincinnati, Ohio 45229-3026 | 1-513-636-4200 | 1-800-344-2462 | TTY:1-513-636-4900
New to Cincinnati Children’s or live outside of the Tristate area? 1-877-881-8479
© 1999-2016 Cincinnati Children's Hospital Medical Center